
Caribou Biosciences (CRBU) Stock Forecast & Price Target
Caribou Biosciences (CRBU) Analyst Ratings
Bulls say
Caribou Biosciences is projected to have a positive outlook in the coming years, with its 1Q26 net loss of $0.26 per share being narrower than previously estimated and a projected full-year 2026 net loss of $1.23 per share. With a solid cash position of $118.6M and upcoming catalysts such as longer follow-up data from the Phase 1 ANTLER trial and initial dose expansion data for CB-011, the company is set to make strides in developing allogeneic CAR-T cell therapies.
Bears say
Caribou Biosciences is currently a risky investment due to its negative cash flow, low probability of approval for its lead assets, and potential delays in advancing these assets to the next stage. Additionally, the company faces long-term dilution risk and a competitive landscape, which could hinder its overall success. Upcoming catalysts may provide some insight into the efficacy of its lead assets, but these are still several years away.
This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction
Start investing in Caribou Biosciences (CRBU)
Order type
Buy in
Order amount
Est. shares
0 shares